Boehringer Ingelheim GmbH and Eli Lilly and Company

EU Scientific Committee Recommends Approval of Cymbalta and Xeristar for Treatment of Major Depressive Episodes

    Indianapolis, Indiana and Ingelheim, Germany (ots/PRNewswire) - Eli Lilly and Company and Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes. The CHMP has recommended that the European Commission authorize the drug to be marketed. If approved, this pharmaceutical treatment for depression will be marketed throughout the European Union by Lilly under the brand name Cymbalta(R) and by Boehringer Ingelheim under the brand names Cymbalta and, in Greece, Italy and Spain, as Xeristar(R).

    The European Commission is expected to grant marketing authorization within the next few months. Duloxetine for major depressive disorder was recently approved by the U.S. Food and Drug Administration and launched in the United States.

    The CHMP, comprised of regulators from the European Union countries, based its positive opinion on its review of a comprehensive data package of duloxetine in the treatment of major depressive episodes. The submission package to support the efficacy and safety of duloxetine consisted of data collected from studies that enrolled nearly 3,000 patients with depression. The European Medicines Agency issued a press release communicating the following: "The benefits with Cymbalta are its demonstrated statistical superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale (HAM-D) total score (including both the emotional and somatic symptoms of depression). ... The CHMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit to risk balance for Cymbalta and therefore recommends the granting of the marketing authorisation."

    Duloxetine is also being studied for the treatment of stress urinary incontinence and diabetic neuropathic pain, conditions believed to respond to treatment with medicines that affect the neurotransmitters serotonin and norepinephrine. On 11 August 2004 the European Commission granted marketing authorization throughout the European Union for duloxetine, for the treatment of moderate-to-severe stress urinary incontinence in women, to be marketed under the brand name Yentreve(R).

    Eli Lilly and Company and Boehringer Ingelheim

    In November 2002, Eli Lilly and Company and Boehringer Ingelheim signed a long-term agreement to jointly develop and commercialize duloxetine hydrochloride. This partnership covers most countries worldwide with few exceptions. In the USA, the collaboration excludes neuroscience indications.

    About Eli Lilly and Company

    Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at .

    About Boehringer Ingelheim

    The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2003, Boehringer  Ingelheim posted net sales of 7.4 billion euro while spending more than one  fifth of net sales in its largest business segment, Prescription Medicines,  on research and development.

    For more information please visit .

    This press release contains forward-looking statements about the potential of duloxetine for the treatment of depression and reflects Lilly's and Boehringer Ingelheim's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of commercialization. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly and Boehringer Ingelheim undertake no duty to update forward-looking statements.


ots Originaltext: Eli Lilly and Company; Boehringer Ingelheim
Im Internet recherchierbar:

Jennifer Yoder of Eli Lilly and Company, Work:  +1-317-433-3445,
Mobile: +1-317-652-0912; or Ursula Bardon of Boehringer Ingelheim
GmbH, +49-6132-77-2622/ Photo:  NewsCom:; PRN Photo Desk,

Weitere Meldungen: Boehringer Ingelheim GmbH and Eli Lilly and Company

Das könnte Sie auch interessieren: